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Antipsychotic drug use and risk of stroke
and myocardial infarction: a systematic
review and meta-analysis
Sanja Zivkovic1, Chan Hee Koh2†, Nandita Kaza2† and Caroline A. Jackson1*
Abstract
Background: The effect of antipsychotic (AP) drugs on risk of stroke and myocardial infarction (MI) remains unclear
due to methodological limitations of, and inconsistencies across, existing studies. We aimed to systematically review
studies reporting on the associations between AP drug use and stroke or MI risk, and to investigate whether associations
differed among different sub-populations.
Methods: We searched Medline, EMBASE, PsychINFO and Cochrane Library (from inception to May 28, 2017)
for observational studies reporting on AP drug use and MI or stroke occurrence. We performed random-effects meta-
analyses for each outcome, performing sub-groups analyses by study population – specifically general population
(i.e. those not restricted to patients with a particular indication for AP drug use), people with dementia only and
psychiatric illness only. Where feasible we performed subgroup analyses by AP drug class.
Results: From 7008 articles, we included 29 relevant observational studies, 19 on stroke and 10 on MI. Results of
cohort studies that included a general population indicated a more than two-fold increased risk of stroke, albeit
with substantial heterogeneity (pooled HR 2.31, 95% CI 1.13, 4.74, I2 = 83.2%). However, the risk among patients
with dementia was much lower, with no heterogeneity (pooled HR 1.16, 95% CI 1.00, 1.33, I2 = 0%) and there was
no clear association among studies of psychiatric populations (pooled HR 1.44, 95% CI 0.90, 2.30; substantial
heterogeneity [I2 = 78.8])). Associations generally persisted when stratifying by AP class, but few studies reported
on first generation AP drugs. We found no association between AP drug use and MI risk (pooled HR for cohort
studies: 1.29, 95% CI 0.88, 1.90 and case-control studies: 1.07, 95% CI 0.94, 1.23), but substantial methodological
and statistical heterogeneity among a relatively small number of studies limits firm conclusions.
Conclusions: AP drug use may be associated with an increased risk of stroke, but there is no clear evidence that
this risk is further elevated in patients with dementia. Further studies are need to clarify the effect of AP drug use
on MI and stroke risk in different sub-populations and should control for confounding by indication and stratify
by AP drug class.
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Background
Major mental disorders represent a growing and, until
relatively recently, under-recognized global public health
burden. Schizophrenia, bipolar disorder, major depression
and anxiety feature among the top 20 causes of years lived
with disability (YLD) [1] and are associated with marked
premature mortality [2–4]. Much of this excess mortality
is due to a higher burden of cardiovascular and cerebro-
vascular disease (largely ischaemic heart disease and
stroke) compared to the general population [5–7]. Several
factors related to mental illness, including low socio-
economic status, lifestyle, physical comorbidities, genetic
predisposition and healthcare access [7–9] could contri-
bute to increased cardio- and cerebrovascular disease
incidence in this vulnerable group. Prescription medi-
cation, including antipsychotic (AP) drug use, has also
been raised as a possible cardiovascular and cerebrovascu-
lar disease risk factor, potentially operating through effects
on body weight, metabolic factors and thrombosis [10].
Despite their potential to increase risk of circulatory
disease, AP drugs are also being increasingly used off-
label, for the treatment of dementia, anxiety, insomnia
and post-traumatic stress [11], with little understanding
of the long-term side-effects, including risks of major
cardiovascular events such as myocardial infarction and
stroke. Their increased use in patients with dementia is
particularly concerning, with around 20% of patients
with dementia in nursing homes in the USA and UK
treated with APs [12, 13]. Use of these drugs in this
population has been linked to increased risk of stroke as
well as other adverse outcomes, including increased
mortality [14] and thus regulatory bodies have discour-
aged the use of AP drug use in people with dementia [15].
However, the evidence for increased stroke risk is based
largely on analyses of serious adverse events in rando-
mized controlled trials of AP drugs in patients with de-
mentia [10, 16, 17]. Confirmation of the appropriateness
of these attached warnings to AP drug use is important,
given that pharmacological alternatives for the treatment
of behavioral and psychological symptoms of dementia
are quite limited [18].
A number of observational studies have reported on the
association between AP use and stroke risk, but until very
recently these had not been systematically reviewed. Since
commencing the present review, one systematic review
and meta-analysis has been published which concluded
that first generation, but not second-generation AP drug
use was associated with an increased risk of cerebrovascu-
lar disease. The authors also reported that among those
with dementia in particular, use of any AP was associated
with a low risk of cerebrovascular disease [19]. However,
this study identified almost half as many studies as in the
present review, thus omitting relevant additional studies
on this topic. Earlier reviews focused on summarizing the
effects of AP drug use specifically in the elderly or those
with dementia [10, 20], the most recent of which suggests
that AP drug use may be associated with an increased risk
of stroke in this population [20]. Existing systematic
reviews on the association between AP drug use and risk
of myocardial infarction (MI) are conflicting. The first
review concluded that the evidence for an association is
inconclusive [21], whereas a more recent review con-
cluded that AP drug use is associated with an increased
risk of MI [22]. Interestingly, a subsequent additional
review (which was published after we completed the
screening phase of the present review) included the same
studies as this previous review, but drew different, more
cautious, conclusions [23]. There is therefore a lack of
clarity on the associations between AP drug use and the
occurrence of major cardio- and cerebrovascular events.
To address this, we performed a systematic review and
meta-analysis of studies reporting on the association
between antipsychotic drug use and risk of stroke and MI.
Methods
Search strategy
We searched Embase, MEDLINE, PsychINFO (via OVID)
and the Cochrane Library from their origin to May 28,
2017 using a comprehensive search strategy comprising
medical subject heading terms and free text words for the
exposure (AP drugs) and outcomes (stroke and MI) of
interest (Additional file 1). We restricted our search to
English language articles only and perused reference lists
from previous reviews and relevant included studies to
identify any additional studies. The first reviewer (SZ) and
one of 2 second reviewers (NK and AK) independently
screened all titles and abstracts, and, for potentially rele-
vant studies, screened full text articles to determine eligi-
bility for inclusion. We included conferences abstracts
that were indexed in the search engines.
Inclusion and exclusion criteria
We sought studies that included a general population
(i.e. those not restricted to patients with a particular
indication for AP drug use) or people with specific mental
disorders often treated with AP drugs (e.g. schizophrenia,
bipolar disorder, major depression or dementia), and com-
pared AP drug use versus no AP drug use in relation to
risk of stroke or MI. We anticipated that confounding by
indication [24] could be a limitation of many studies and
so we did include studies which attempted to address this
by comparing people taking APs versus those on other
medications for mental illness (but not taking APs). Con-
founding by indication could occur because the indication
for AP drug use, such as having a serious mental illness, is
itself associated with increased risk of stroke or MI, thus
potentially leading to a spurious association between AP
drug use and stroke or MI risk. We excluded studies: that
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compared AP drug use with active comparators; and that
reported only on stroke or MI mortality, since we were
interested in the association between AP drug use and
risk of stroke/MI occurrence and not death following
stroke/MI. Where two studies overlapped in terms of
study population we selected the larger of the two studies.
Data extraction
Pairs of reviewers (SZ and CK or SZ and NK) indepen-
dently extracted data on: study design; sample size; coun-
try; patient population; baseline characteristics of each
comparator arm; definition of exposure and outcome;
ascertainment of exposure and outcome; length of and
loss to follow up; number of events; main results including
crude and adjusted effect estimates with accompanying
95% confidence intervals; method of statistical analysis;
and adjustments for confounders. A fourth investigator
(CAJ) reviewed any disagreements. We assessed study
quality and risk of bias using the SIGN checklist [25].
Meta-analysis
We used Stata version 14.0 to conduct meta-analyses on
the association between AP drug use and each of stroke
and MI occurrence. We pooled studies according to
study design and type of effect estimate, grouping to-
gether: cohort and nested case-control studies reporting
hazard ratios (HRs); cohort/nested case-control studies
reporting odds ratios (ORs); and standard case-control
studies reporting ORs. For stroke, we stratified these
meta-analyses by type of study population, creating sub-
groups of studies that included: patients diagnosed with
psychiatric disorders; patients diagnosed with dementia;
and a general population with unspecified indications
for AP use. Whilst we summarized findings from self-
controlled case series and case-crossover studies, we did
not include these studies in our meta-analyses, given the
differences in study design and analytical approach. Due
to a fewer number of studies, almost all of which were
conducted using general population data, we were un-
able to perform sub-group analysis by type of study
population when pooling together studies reporting on
MI. We pooled effect estimates using the random effects
method, assessing heterogeneity using the I2 and Chi2 sta-
tistics. In accordance with Cochrane Collaboration guid-
ance, we interpreted heterogeneity based on I2 values as
follows: 0–40% - may not be important; 30–60% - may be
moderate; 50–90% - may be substantial; 75–100% may be
considerable. We interpreted I2 values in the context of
the magnitude and direction of effects as well as the chi2
p-value for heterogeneity. In order to improve compa-
rability between studies, where results on the association
between AP drug use and cerebrovascular disease risk
were reported for different exposure periods we included
the longest exposure period, often defined as the ‘ever
exposed’ period, or as close to is as possible. We narra-
tively summarized findings from self-controlled studies,
since it is methodologically inappropriate to pool this type
of study design with cohort or case-control studies. In
addition, methodological differences (including the re-
porting of different types of effect estimates) precluded
separate pooling of these studies. Where outcome risks by
type of AP drug were reported (i.e. first generation
antipsychotic [FGA] or second generation antipsychotic
[SGA]), we included these separately in the analyses, thus
obtaining sub-group summary effect estimates for type of
AP as well as overall summary estimates. If studies
reported on multiple APs separately, we included the
largest group of AP users in our meta-analysis.
We reported the findings of this systematic review
in accordance with the PRISMA and MOOSE guide-
lines [26, 27].
Results
Our search strategy identified 8163 articles. After de-
duplication we screened 7008 titles and abstracts, 146 of
which were potentially relevant. Following full-text review
of these articles, we included 19 articles reporting on
cerebrovascular disease [28–46] and 10 reporting on
MI [31, 47–55] in the review (Fig. 1).
Quality assessment of included studies
All but three studies [38, 53, 54] used routine ad-
ministrative health datasets to ascertain AP prescri-
bing and stroke/MI ascertainment, thus eliminating
reporting bias and minimizing loss to follow-up
(Additional file 1: TablesS1 and S2). The remaining
three studies relied on self-reported AP drug use
and/or outcome occurrence. Twelve studies reporting
on stroke and 7 reporting on MI reported baseline
characteristics of comparison groups. All studies
adjusted for age and sex and the majority also
accounted for cardiovascular comorbidities. Among
studies that included a general population (e.g. a co-
hort identified from primary care/medical insurance
records), indication for AP drug use was generally
not accounted for. One study compared stroke and
MI outcomes in people taking SGAs versus a com-
parison group taking anti-depressants but not SGAs,
in order to partially control for confounding factors
associated with initiation of SGAs (related to mental
illness) [31]. Socioeconomic status and lifestyle factors,
which may be associated with the disorder for which AP
drug medication was prescribed, were rarely adjusted for
(Additional file 1: Tables S3 and S4). We identified one
conference abstract by Wang et al. which was assessed
to be of a reasonable quality overall. However, we
couldn’t assess some elements due to the lack of avail-
able information [55].
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Eight cohort studies [28, 29, 31, 36, 38, 40, 41, 43], 6 case-
control studies (5 nested case-control) [30, 33–35, 37, 39],
two self-controlled case series studies [32, 42], two case-
crossover studies [44, 46] and one case-case-time control
study [45] reported on the association between AP drug use
and stroke risk. Five studies included a population of de-
mentia patients [28, 29, 37, 39, 40], three included patients
with psychiatric disorders [30, 34, 36] and the remaining 11
studies investigated AP drug use in a general population
(Table 1). All but one [38] of the included studies used large
routine medical databases to identify patients, determine
AP drug use and identify outcome. AP drug exposure was
defined as new AP drug use [28, 29, 42, 43] or ‘ever’ AP
drug use. Only 3 studies specified a minimum exposure
period, which ranged from 3 days to 4 weeks [31, 33, 45].
The mean baseline age of study participants varied by
the study populations included (Table 1). The mean age in
studies that included people with dementia only ranged
from 78 to 81 years, whilst studies of patients with psy-
chiatric conditions had a younger range (43 to 57 years).
The age range in studies that included a general popula-
tion was much broader (45 to 85 years), reflecting different
age restrictions and data sources used. Studies were
heterogeneous in terms of follow-up duration, ranging
from 1 week [42] to 12 years [37]. Among studies that
included a general population, the indication for AP drug
use was not reported.
We included all but one [41] of the cohort and case-
control studies in our meta-analysis. We separately
pooled 13 study populations from 8 cohort studies (in-
cluding one nested case-control study reporting HRs)
[28–31, 36, 38, 40, 43] and 9 study populations from 5
case-control studies [33–35, 37, 39]. Overall, among
studies including a general population, use of any AP
drug was associated with a 2.3-fold increased risk of
Fig. 1 Flow diagram of literature search and study selection
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stroke (pooled HR 2.31, 95% CI 1.14, to 4.74), but with
substantial heterogeneity between studies (I2 = 83.2%;
p < 0.001; Fig. 2a). This appeared to be due to larger
effect estimates in the study which examined new (as
opposed to ‘ever’) AP drug use [43]. Findings were more
mixed for studies including only psychiatric patients,
where use of any AP drug was associated with a statisti-
cally non-significant increased risk of stroke (pooled HR
1.44, 95% CI 0.90 to 2.30), with substantial heterogeneity
between studies (Fig. 2a). Similar findings were observed
when we pooled case-control studies, although effect
estimates were weaker and not significant (Fig. 2d).
When we pooled studies that included a general popula-
tion or patients with psychiatric conditions and stratified
by AP drug use, SGA drug use was significantly asso-
ciated with a 71% increased risk of stroke (pooled HR
1.71, 95% CI 1.16 to 2.53; Fig. 2b), again with substantial
heterogeneity between studies (I2 = 74.9%, p = 0.003).
Only two studies reported on FGA drug use, with contra-
dictory findings (Fig. 2b).
Findings between studies of patients with dementia
were more consistent. Use of any AP drug was margi-
nally significantly associated with a 16% increase risk of
stroke among cohort studies (pooled HR 1.16, 95% CI
1.00 to 1.33), with no heterogeneity between studies
(Fig. 2a). Findings were consistent across studies, ir-
respective of whether AP drug use was defined as ‘new’ or
‘ever’. When dementia studies were stratified according to
AP type, neither FGA nor SGA drug use were statistically
significantly associated with stroke risk (pooled HR 1.02,
95% CI 0.65 to 1.60 and pooled HR 1.18, 95% CI 0.83 to
1.68, respectively; Fig. 2c), however this is based on just
two studies in each sub-group. In keeping with findings
from cohort studies, findings from case-control studies
showed no clear association between AP drug use and
stroke risk in studies of patients with dementia (pooled
a b
c d
Fig. 2 Forest plots for the association between antipsychotics and stroke, by study population/antipsychotic class subgroups NB In plots a-c, n/N
represents number of cerebrovascular events/total number in comparison group for those using antipsychotic medication and those not using
antipsychotic medication. Chen (a) = haemorrhagic stroke; Chen (b) = ischaemic stroke. AP = antipsychotic; CI = confidence interval
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OR 0.94, 95% CI 0.66 to 1.33), but there was substan-
tial heterogeneity between studies (I2 = 94.3%, p < 001;
Fig. 2d).
An additional five self-controlled studies (among which
three different variations of the self-controlled approach
were adopted) [32, 42, 44–46] compared pre- and post-
periods of AP drug use for each patient. All five studies
found AP drug use was associated with an increased risk
of stroke, although follow-up was much shorter than in
other study designs, ranging from 1week to 1 year. Three
found a significant association between use of any AP
drug and stroke [32, 45, 46]. Shin found a significant asso-
ciation between SGA drug use and increased stroke risk
(OR 3.90, 95% CI 3.30 to 4.60) [44] while Pratt reported a
significant association between FGA drug use (but not
SGA drug use) and increased stroke risk during the week
following AP drug initiation (IRR 2.25, 95% CI 1.32 to
3.83) [42]. These findings are also consistent with those
from Sacchetti, which found a substantial increased risk of
stroke within one-month post-AP drug use initiation [56].
This study wasn’t included in our review since the
study population overlapped with that of another
study already included [43].
AP drug use and MI risk
Five cohort studies [31, 48, 49, 52, 54], three case control
studies [47, 51, 53], one case crossover study [50] and one
case-case time control study [55] reported on AP drug use
and MI risk (Table 1). Seven studies included a general
population and thus did not specify the indication for AP
drug use [31, 47, 49, 51, 53–55], one included patients
with schizophrenia [48], one included patients with psy-
chiatric illness or dementia disorders [50] and one
included patients with dementia [52]. In five studies the
included population had a mean age of more than 65
years, four included a population aged < 50 years, and one
study did not report on age of participants. The follow-up
period ranged from 90 days [49] to 13 years [54].
Study findings among five cohort studies were inconsist-
ent, with substantial heterogeneity between studies report-
ing HRs (I2 = 62.6%; p = 0.05) and those reporting ORs
(I2 = 65.7; p = 0.09). There were too few studies to allow
sub-group analysis by type of study population and a lim-
ited sub-group analysis by AP drug type (Fig. 3).
Similarly, there was considerable heterogeneity be-
tween the findings from case-control studies (I2 = 78.3%;
p = 0.003). Given this statistical heterogeneity, along with
methodological heterogeneity in terms of study population
and type of AP drug included, summary estimates should
be interpreted with caution. Based on existing studies,
there was no clear evidence that AP drug use was associ-
ated with increased risk of MI (Fig. 3).
In contrast to the findings from cohort and case-
control studies, findings from the two self-controlled
studies were consistent in showing a significant asso-
ciation between AP drug use and increased risk of
MI (50,55). As with the self-controlled studies that
examined stroke outcomes, these studies differ from
cohort and case-control studies in terms of including a
much shorter follow-up period (30–120 days; Table 1).
Discussion
We found that AP drug use is associated with an in-
creased risk of stroke, but that this association is much
weaker in studies that included only patients with demen-
tia than in studies which included the general population
or patients with psychiatric disorders. Among study popu-
lations that were not restricted to patients with dementia,
an increased stroke risk was observed for SGAs only, with
less available data on FGAs. However, with the exception
of the subgroup of dementia-focused studies, in all
analyses there was substantial statistical heterogeneity
between studies, even after stratifying by study population
and type of AP drug.
There was no clear evidence of an association between
AP drug use and risk of MI. However, substantial statis-
tical and methodological heterogeneity between among a
relatively small number of studies on MI risk makes it
difficult to draw firm conclusions.
We are aware of just one other systematic review and
meta-analysis on AP drug use and stroke risk, published
during the conduct of our review [19]. This review
included fewer studies than we did, but this is partly due
to our use of a broader set of inclusion criteria. Whilst the
authors of the previous review did perform sub-group
analyses, these were not identical to those that we per-
formed, which makes comparability of findings difficult.
Consistent with the findings of our review, the authors did
report a weaker association between AP drug use and
stroke risk among the dementia population compared to
studies not restricted to this sub-population. We found
that AP drug use was associated with a 16% increased
odds of stroke in those with dementia, which was similar
to the 17% (OR 1.17, 95% CI 1.08 to 1.26) reported by
Hsu and colleagues [19]. Previous narrative reviews drew
similar conclusions, but focused on summarizing evidence
on AP use and stroke risk in the elderly or those with
dementia [10, 20]. Interestingly, Sacchetti concluded that
the excess cerebrovascular disease risk does not appear to
be confined to patients with dementia, but applies to
elderly patients in general [20]. In contrast to our findings,
Hsu et al. concluded that the association with stroke risk
is stronger for FGAs than SGAs [19]. Conversely, although
relatively few studies reported findings by AP drug type,
we found more convincing evidence of an association
between SGAs and stroke risk, with more limited data
available for FGAs. However, there are a number of key
differences between the two reviews, which may account
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for these differing conclusions. In addition to including a
greater number of studies, we also stratified by study
design in all analyses. In contrast, Hsu et al. appeared
to have pooled studies irrespective of study popula-
tion, type of study and type of effect estimate. Interest-
ingly, a recent meta-analyses found no difference in risk of
cerebrovascular events in those prescribed FGAs versus
SGAs when pooling data from 5 studies that directly com-
pared the effect of FGAs versus SGAs on cerebrovascular
disease risk in people with dementia [57].
As with stroke, studies on MI were heterogeneous in
terms of study design, AP drug type, study population
Fig. 3 Forest plots for the association between APs and MI, by study design and AP class. *Number of MI events in the group prescribed
antipsychotic drugs (exposed) and those not prescribed antipsychotic drugs (non-exposed). †Number of people prescribed antipsychotic drugs
among cases (those with MI) and controls (those without MI). AP = antipsychotic; HR = hazard ratio; MI = myocardial infarction; NR = not reported
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and measure of effect. Although we found no clear evi-
dence that AP drug use is associated with increased MI
risk, the inconsistency in findings across studies, in the
presence of substantial statistical heterogeneity, makes it
difficult to draw firm conclusions. This concurs with the
findings of a previous review by Brauer [21], despite our
review having included an additional 5 studies. Our
conclusion contradicts that of a more recent review, which
concluded that there is an association between AP drug
use and MI risk, albeit with substantial heterogeneity
between pooled effect estimates [22]. We identified two
additional studies not included in this review [31, 49].
Whilst the authors of this review included sub-group
analyses, they still pooled results from methodologically
different studies or different study sub-populations and
often pooled different effect estimates, which affects
reliability and interpretability of pooled results. This may
account for the contradiction in findings between the
present review and this previous review. Our conclusions
do however concur with those of Huang et al., who per-
formed a similar review concurrent to our own review
[23]. In line with our findings, the authors conclude that
there is insufficient evidence to draw firm conclusions
about the association between APs and MI risk and high-
light the need for further prospective studies in this area.
Given that the conclusions drawn by Yu et al. and Huang
et al. are based on the same included studies, but are
inconsistent, our review makes an important further
addition to the literature, providing support for the
conclusions and recommendations by Huang et al. In our
review we did not synthesize data on differing time
periods of AP drug exposure and risk of stroke and MI.
Effect estimates for different AP drug exposure periods
were reported in relatively few studies, which were ex-
tremely methodologically heterogeneous, limiting formal
synthesis. However, within individual studies, there is
some evidence that the risk of stroke and MI might be
greater in the very acute period of AP drug use, with a
lower risk in the longer term. This is consistent with
findings from other reviews [20, 22, 23]. These findings
largely stem from studies that included a general, older
population and so it is unclear whether such a pattern
is also present amongst people with major psychiatric
disorders for which AP drugs are indicated. Given that
relatively few studies have investigated this across
different sub-populations, further careful investigation
in future studies is needed.
There is biological plausibility for a causal association
between AP drug use and increased risk of vascular
disease. AP drug use has long been associated with weight
gain, which is possibly due to the AP drug affinity for the
histamine-1 receptor which, when blocked, modulates
feeding behavior and stimulates weight gain [58, 59] and
the effect of AP drugs on hypothalamic regulation
[60, 61]. AP drug use is also associated with risk of
metabolic syndrome, perhaps through the increased
affinity for specific serotonin, muscarinic and histamine re-
ceptors, among others [62]. APs may also increase risk of
thrombosis. A recent meta-analysis [63] found that AP
drug use is associated with a 50% increased odds of venous
thromboembolisms, albeit with substantial heterogeneity
between studies, with possible underlying mechanisms
including increased platelet aggregation, AP drug-induced
sedation leading to venostasis and clot formation [64]. APs
are also thought to be associated with insulin resistance
and weight gain, which in turn are risk factors for
cardio- and cerebro-vascular disease [65].
Our review benefits from a number of strengths: we
identified studies using a detailed and comprehensive
search strategy; we performed meta-analyses using a
carefully considered approach which took due account of
important methodological differences between studies,
including study design and type of effect estimate
(whereas previous meta-analyses have been less care-
ful in their meta-analytical approach); and we assessed
individual study methodological quality, paying particular
attention to the potential for confounding in many
studies, which previous reviews have rarely highlighted.
Our review has limitations, mainly due to shortcom-
ings of individual studies and the challenges of meaning-
fully synthesizing such heterogeneous studies. Whilst
selection and information bias were minimized through
the use of routinely collected health datasets in almost
all studies, confounding by indication is a major limi-
tation, since having a major mental disorders is itself
associated with increased risk of stroke and MI [5]. The
excess risk of cardiovascular disease in people with
major mental illness is thought to be multifactorial and
to include poor lifestyle behaviours (such as smoking,
alcohol misuse, physical inactivity and obesity), increased
risk of diabetes, shared genetic factors and direct physio-
logical effects of the mental illness [66–68]. Whilst APs
might themselves increase the risk of cardiovascular
disease, particularly through weight gain, it is interesting
that metabolic dysregulation for example, has been
observed in AP naïve people with major mental illness
[69]. In the studies identified in our review confounders
such as lifestyle factors and socioeconomic status were
rarely adequately adjusted for. The definition of stroke
varied considerably across studies, with some also
including non-stroke cerebrovascular disease ICD codes
and others adopting a very narrow definition of stroke.
Finally, studies were also heterogeneous in their defi-
nition of AP drug use and duration of follow-up varied
widely, from just weeks to 13 years.
Further research is needed to address the gaps identified
in this review. For ethical reasons, RCTs in this area are
less feasible than observational studies, since, for some
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conditions, there are no suitable potential alternatives to
AP drug treatment. However, where potential alternative
treatments do exist, RCTs may be appropriate. In the de-
mentia population for example, future studies could
examine how the risk of stroke and MI amongst AP drug
users compares to alternative treatment for behavioural
and psychotic symptoms. For example, findings from a co-
hort study conducted by Finkel may suggest that AP drug
use has a potentially lower risk of stroke compared to the
use of benzodiazepines in dementia patients [70]. Where
RCTs are not feasible, robust cohort and case-control
studies should be performed. Such studies should be suffi-
ciently large in order to be adequately powered to detect
significant associations with high precision. Pooling of in-
dividual patient data across multiple settings would be
one approach to enhance study power. Routinely collected
national health data which contains information on men-
tal health diagnosis and treatment, previous and subse-
quent cardiovascular events and confounding factors
would be the ideal data source for future studies. This re-
lies on the existence of robust mental health registries
linked to other health data or linkage of primary and sec-
ondary care data as well as prescription data, which exists
in relatively few settings. However, such studies would
eliminate bias, facilitate control of confounders and estab-
lish temporality between AP drug use and cardiovascular
outcome, particularly in case-control studies. Future stud-
ies should also distinguish between FGA and SGA users,
given their differing pharmacological properties and po-
tentially different risk of stroke and MI. Confounding by
indication should be minimized and risk estimates should
be determined based on indication for AP drug use. Stud-
ies should also assess the risk over multiple time periods
in order to clarify whether and how the association may
change with time. A minimum duration of AP use should
also be clearly established (such as multiple prescriptions)
especially if large registry databases are used to ascertain
exposure.
In the absence of conclusive evidence that AP drug
use increases risk of stroke or MI, we recommend that
clinicians should carefully weigh the potential benefits
and risks of AP drug use on an individual basis, and
evaluate cardiovascular risk prior to AP drug initiation
and during treatment. We urge clinical caution in the
initiation of off-label AP drug use and encourage the
exploration of alternative treatment routes.
Conclusions
In conclusion, there is some evidence that AP drug use is
associated with an increased risk of stroke, but no clear
evidence that it is associated with an increased risk of MI.
The risk of stroke was less apparent in studies specifically
reporting on a population with dementia. However, these
conclusions are drawn with the caveat that there was
substantial methodological and statistical heterogeneity
between studies and we highly recommend further meth-
odologically robust studies which control for confounding
factors, account for confounding by indication and exam-
ine associations by AP drug type and exposure period.
Whilst further research is undertaken, psychiatrists and
other physicians prescribing antipsychotic medications to
people with or without a major mental disorder should be
vigilant in monitoring and improving their cardiovascular
risk profile.
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